Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments

Nephrology

Volumn 14, Issue 5, 2009, Pages 455-461

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Haemodialysis; Heparin; Low molecular weight heparin

Indexed keywords

ANTITHROMBIN; DALTEPARIN; ENOXAPARIN; HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; CLINICAL PRACTICE; DRUG HALF LIFE; DRUG POTENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIAFILTRATION; HEMODIALYSIS; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS;

ANTICOAGULANTS; DRUG COSTS; ENOXAPARIN; HEMODIAFILTRATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RENAL DIALYSIS; THROMBOCYTOPENIA;

EID: 68349096347     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01135.x     Document Type: Review

References (21)

1. Davenport A. Anticoagulation options for paediatric haemodialysis. Hemodial. Int. 2003 7 : 1 10.
2. Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib. Nephrol. 2004 144 : 228 38.
3. Davenport A. Intradialytic complications during haemodialysis. Hemodial. Int. 2006 10 : 162 7.
4. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane) and danaparoid (Orgaran) in stable chronic haemodialysis patients. Am. J. Kidney Dis. 2002 40 : 990 5.
5. Klingel R, Schwarting A, Lotz J, Eckert M, Hohman V, Hafner G. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic haemodialysis. Kidney Blood Press. Res. 2004 27 : 211 17.
6. Lord H, Jean N, Dumont M, Kassis J, Leblanc M. Comparison between tinzaparin and standard heparin for chronic haemodialysis in a Canadian centre. Am. J. Nephrol. 2002 22 : 58 66.
7. Davenport A. Anticoagulation during dialysis and/or continuous therapy. LMWH or heparin versus citrate. Eur. J. Hosp. Pharm. 2007 13 : 64 6.
8. Hofbauer R, Moser D, Frass M et al. Effect of anticoagulation on blood membrane interactions during haemodialysis. Kidney Int. 1999 56 : 1578 83.
9. Davenport A, Lai KN, Hertel J, Caruana RJ. Anticoagulation. In : Daugirdas JT, Blake PG, Ing TS (eds). Handbook of Dialysis, 4th edn. Amsterdam : Wolters Kluwer Health, 2007 204 18.
10. Greaves M. Control of anticoagulation subcommittee of the scientific and standardization committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and standardization committee communications on behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemostst. 2002 87 : 163 4.
11. Brophy DF, Martin EJ, Gehr TW, Care ME Jr. Enhanced anticoagulation activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am. J. Kidney Dis. 2004 44 : 270 7.
12. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low molecular weight heparin (enoxaparin sodium) and standard fractionated heparin for haemodialysis. Nephrol. Dial. Transplant. 1999 14 : 2698 703.
13. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol. Nefrol. 2006 58 : 171 80.
14. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int. 1991 40 : 496 500.
15. Lai KN, Ho K, Cheung RC et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidaemia in patients on maintenance haemodialysis. Int. J. Artif. Organs. 2001 24 : 447 55.
16. Oster JR, Singer I, Fishman LM. Heparin induced aldosterone suppression and hyperkalaemia. Am. J. Med. 1995 98 : 575 86.
17. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for haemodialysis patients with end stage renal failure: A meta analysis of randomised controlled trials. J. Am. Soc. Nephrol. 2004 15 : 192 206.
18. European Best Practice Guidelines. V1-V5. Haemodialysis and prevention of system clotting(V1-V2); prevention of clotting in the haemodialysis patients with elevated bleeding risk (V3); heparin induced thrombocytopenia (V4); and side effects of heparin (V5). Nephrol. Dial. Transplant. 2002 17 (Suppl 7 63.
19. Davenport A. Heparin induced thrombocytopenia during renal replacement therapy. Hemodial. Int. 2004 8 : 295 303.
20. Charif R, Davenport A. Heparin-induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy. Hemodial. Int. 2006 10 : 235 40.
21. Blossom DB, Kallen AJ, Patel PR et al. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008 359 : 2674 84.